BioSpace News Archive

CINCINNATI, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2019. First Quarter Fiscal 2020 Highlights: Diagnostics segment delivered nearly $35 million in revenues; fourth consecutive quarter above $33 million, signaling continued stabilization of this business; Positive customer feedback for our revogene™ molecular diagnostics system continues to build; Diagnostics segment new product

SAN DIEGO, Feb. 07, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, announced today that it has transferred its Nasdaq listing to the Nasdaq Capital Market and is in compliance with the stockholders’ equity standard to remain listed on the Nasdaq Capital Market. About TRACON TRACON develops targeted therapies for cancer and ophthalmic diseas

Allied Corp. (“Allied”) (OTCQB: ALID) – an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions to address today’s medical issues – is pleased to announce the signing of a non-binding letter of intent between Hollister Biosciences Inc. (“Hollister”) and Allied Corp. affiliate Tactical Relief, LLC (“Tactical Relief”) with respect to the joint development and introduction of TACTICAL RELIEF™ branded products to the California market.

- Reports Full-Year Diluted EPS of $5.28 on a GAAP Basis, an Increase of 44.3 Percent; Adjusted Diluted EPS of $8.94, an Increase of 13.0 Percent - Full-Year Net Revenues Were $33.266 Billion, an Increase of 1.6 Percent on a GAAP Basis; Adjusted Net Revenues Grew 2.7 Percent Operationally; Excluding the Unfavorable Impact of International HUMIRA Net Revenues Due to Biosimilar Competition, Full-Year Adjusted Net Revenues Grew 9.9 Percent Operationally - Full-Year U.S. HUMIRA N

ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Dr. Stephen Dilly has joined its Board of Directors.

Feb. 7, 2020 13:00 UTC Experienced industry leader to head Complexa’s corporate and business development programs BERWYN, Pa.--( BUSINESS WIRE )-- Complexa Inc. today announced the appointment of Elisabeth Leiderman, MD, MBA, as Chief Business Officer. Dr. Leiderman formerly served as Senior Vice President, Head of Corporate Development for Fortress Biotech where she led strategy and oversight for all aspects of corporate development for the company’s 10 subsidiaries.

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, will today present data on OTX-TIC, a long acting travoprost intracameral implant for the treatment of patients with primary open angle glaucoma or ocular hypertension.

Jeff Needham to retire; Rich Sorota appointed to lead Consumer Self-Care Americas business

Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSX VENTURE:ASG) is pleased to announce that it has closed the final tranche of its non-brokered private placement offering (the “Offering”). Under the final tranche of the Offering, the Company issued 3,432,000 units (the “Units”) at a price of CDN$0.25 per Unit for aggregate gross proceeds of approximately CDN$858,000.

CHARLOTTESVILLE, Va., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today announced that it has been granted Patent Number EP2540696 B1 from the European Patent Office. This patent relates to pharmaceutical compositions of trans sodium croce